10x Genomics (TXG) Operating Expenses (2018 - 2026)

10x Genomics (TXG) has 9 years of Operating Expenses data on file, last reported at $123.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 14.88% year-over-year to $123.2 million; the trailing twelve-month figure through Mar 2026 stood at $483.3 million (down 19.37% YoY), and the FY2025 full-year result was $504.9 million, down 17.1% from the prior year.
• Operating Expenses declined to $123.2 million in Q1 2026, from $132.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $190.3 million in Q3 2023 to a low of $95.0 million in Q2 2025.
• A 5-year average of $145.6 million and a median of $146.0 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 35.28% in 2023 and plunged 34.94% in 2025, its largest moves.
• Tracing TXG's Operating Expenses over 5 years: stood at $142.5 million in 2022, then climbed by 19.98% to $171.0 million in 2023, then retreated by 5.95% to $160.8 million in 2024, then fell by 17.54% to $132.6 million in 2025, then fell by 7.06% to $123.2 million in 2026.
• Business Quant data shows TXG's Operating Expenses at $123.2 million in Q1 2026, $132.6 million in Q4 2025, and $132.5 million in Q3 2025.